CA2138026C - Novel 1,4-dihydroquinoxaline-2,3-diones and uses therefor as glycine receptor antagonists - Google Patents
Novel 1,4-dihydroquinoxaline-2,3-diones and uses therefor as glycine receptor antagonists Download PDFInfo
- Publication number
- CA2138026C CA2138026C CA002138026A CA2138026A CA2138026C CA 2138026 C CA2138026 C CA 2138026C CA 002138026 A CA002138026 A CA 002138026A CA 2138026 A CA2138026 A CA 2138026A CA 2138026 C CA2138026 C CA 2138026C
- Authority
- CA
- Canada
- Prior art keywords
- dihydroquinoxaline
- dione
- halo
- nitro
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/40—Benzopyrazines
- C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/50—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to ring nitrogen atoms
- C07D241/52—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/50—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to ring nitrogen atoms
- C07D241/54—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Optics & Photonics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Rheumatology (AREA)
- Psychology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US90308092A | 1992-06-22 | 1992-06-22 | |
US99516792A | 1992-12-22 | 1992-12-22 | |
US07/995,167 | 1992-12-22 | ||
US07/903,080 | 1992-12-22 | ||
US6927493A | 1993-05-28 | 1993-05-28 | |
US08/069,274 | 1993-05-28 | ||
PCT/US1993/005859 WO1994000124A1 (en) | 1992-06-22 | 1993-06-17 | Glycine receptor antagonists and the use thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2138026A1 CA2138026A1 (en) | 1994-01-06 |
CA2138026C true CA2138026C (en) | 2003-09-09 |
Family
ID=27371510
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002138026A Expired - Lifetime CA2138026C (en) | 1992-06-22 | 1993-06-17 | Novel 1,4-dihydroquinoxaline-2,3-diones and uses therefor as glycine receptor antagonists |
Country Status (15)
Country | Link |
---|---|
US (3) | US5514680A (sv) |
EP (1) | EP0647137B1 (sv) |
JP (1) | JP3301024B2 (sv) |
KR (1) | KR100304017B1 (sv) |
AT (1) | ATE404201T1 (sv) |
AU (1) | AU672617B2 (sv) |
CA (1) | CA2138026C (sv) |
DE (1) | DE69334237D1 (sv) |
DK (1) | DK0647137T3 (sv) |
ES (1) | ES2313714T3 (sv) |
FI (1) | FI120094B (sv) |
NO (1) | NO310022B1 (sv) |
NZ (1) | NZ254404A (sv) |
PT (1) | PT647137E (sv) |
WO (1) | WO1994000124A1 (sv) |
Families Citing this family (82)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9100028D0 (en) * | 1991-01-02 | 1991-02-20 | Ici Plc | Compounds |
GB9212308D0 (en) * | 1992-06-10 | 1992-07-22 | Ici Plc | Therapeutic compositions |
US5834479A (en) * | 1993-03-05 | 1998-11-10 | Mayer; David J. | Method and composition for alleviating pain |
CA2115792C (en) | 1993-03-05 | 2005-11-01 | David J. Mayer | Method for the treatment of pain |
IL109397A0 (en) * | 1993-04-28 | 1994-07-31 | Schering Ag | Quinoxalinedione derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same |
GB9311948D0 (en) * | 1993-06-10 | 1993-07-28 | Zeneca Ltd | Substituted nitrogen heterocycles |
US5631373A (en) * | 1993-11-05 | 1997-05-20 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon, Eugene Oregon | Alkyl, azido, alkoxy, and fluoro-substituted and fused quinoxalinediones |
IL112235A (en) * | 1994-01-03 | 2000-06-29 | Acea Pharm Inc | 1,4-dihydro-pyrido¬2,3-b¾pyrazine-2,3-dione (5 or 8) oxide derivatives and pharmaceutical compositions containing them |
FR2717812B1 (fr) * | 1994-03-28 | 1996-05-10 | Rhone Poulenc Rorer Sa | Indeno[1,2-e]pyrazine-4-ones, leur préparation et les médicaments les contenant. |
FR2717805B1 (fr) * | 1994-03-28 | 1996-05-10 | Rhone Poulenc Rorer Sa | Dérivés de 5H-indeno[1,2-b]pyrazine-2,3-dione, leur préparation et les médicaments les contenant . |
FR2717811B1 (fr) * | 1994-03-28 | 1996-04-26 | Rhone Poulenc Rorer Sa | Dérivés d'imidazo[1,2-a]pyrazine-4-one, leur préparation et les médicaments les contenant. |
FR2717813B1 (fr) * | 1994-03-28 | 1996-05-10 | Rhone Poulenc Rorer Sa | Dérivés d'imidazo[1,2-a]indeno[1,2-e]pyrazine-4-one, leur préparation et les médicaments les contenant . |
HU217837B (hu) * | 1994-05-18 | 2000-04-28 | EGIS Gyógyszergyár Rt. | Savamidok, ezeket tartalmazó gyógyászati készítmények és eljárás a hatóanyagok előállítására |
US5801168A (en) * | 1994-06-09 | 1998-09-01 | Zeneca Limited | Substituted nitrogen heterocycles |
DE4428152A1 (de) * | 1994-06-22 | 1996-01-04 | Basf Ag | Neue Amido-chinoxalindione, ihrer Herstellung und Verwendung |
EP0705834A1 (de) * | 1994-07-27 | 1996-04-10 | Ciba-Geigy Ag | Azaaliphatisch Überbrückte Chinoxalin-2,3-dione |
US5597922A (en) * | 1994-07-29 | 1997-01-28 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon | Glycine receptor antagonist pharmacophore |
EP0705835A1 (de) * | 1994-09-01 | 1996-04-10 | Ciba-Geigy Ag | Oxa- oder thiaaliphatisch überbrückte Chinoxalin-2,3-dione |
GB9418443D0 (en) * | 1994-09-13 | 1994-11-02 | Pfizer Ltd | Therapeutic agents |
GB9419318D0 (en) * | 1994-09-24 | 1994-11-09 | Pfizer Ltd | Therapeutic agents |
US5801183A (en) * | 1995-01-27 | 1998-09-01 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon | Aza and aza (N-oxy) analogs of glycine/NMDA receptor antagonists |
GB9604400D0 (en) | 1996-03-01 | 1996-05-01 | Pfizer Ltd | Compounds useful in therapy |
WO1997046539A1 (en) * | 1996-06-05 | 1997-12-11 | Warner-Lambert Company | Amide derivatives of substituted quinoxaline 2,3-diones as glutamate receptor antagonists |
WO1997049684A1 (en) * | 1996-06-24 | 1997-12-31 | Novo Nordisk A/S | Factor vii-binding reagent |
SK282548B6 (sk) * | 1996-10-24 | 2002-10-08 | Novartis Ag | Substituované aminoalkánfosfónové kyseliny, spôsob ich prípravy, farmaceutické prostriedky, ktoré ich obsahujú, a ich použitie |
HUP0001311A3 (en) * | 1997-02-18 | 2001-07-30 | American Home Products Corp Ma | 5-aminoalkoxy-1,4-dihydroquinoxaline-2,3-diones being dopamine agonists and pharmaceutical compositions containing them |
US5922715A (en) * | 1997-02-18 | 1999-07-13 | American Home Products Corporation | 5-aminoalkoxy-1, 4-dihydroquinoxaline-2, 3-diones |
JP2001522358A (ja) * | 1997-04-18 | 2001-11-13 | アボツト・ラボラトリーズ | 高純度6,7−ジクロロ−5−ニトロ−2,3−ジヒドロキノキサリン−2,3−ジオンの調製方法 |
IL125950A0 (en) * | 1997-09-05 | 1999-04-11 | Pfizer Prod Inc | Methods of administering ampa receptor antagonists to treat dyskinesias associated with dopamine agonist therapy |
US6375957B1 (en) | 1997-12-22 | 2002-04-23 | Euro-Celtique, S.A. | Opioid agonist/opioid antagonist/acetaminophen combinations |
US6277384B1 (en) | 1997-12-22 | 2001-08-21 | Euro-Celtique S.A. | Opioid agonist/antagonist combinations |
PL341309A1 (en) * | 1997-12-22 | 2001-04-09 | Euro Celtique | Method of preventing overdosage of opioidic preparations |
WO1999044612A1 (en) | 1998-03-02 | 1999-09-10 | Cocensys, Inc. | Substituted quinazolines and analogs and the use thereof |
DE19814257A1 (de) * | 1998-03-31 | 1999-10-07 | Asta Medica Ag | Brauseformulierungen |
CA2393688A1 (en) * | 1999-12-09 | 2001-06-14 | Chiron Corporation | Method for administering a cytokine to the central nervous system and the lymphatic system |
US6716449B2 (en) | 2000-02-08 | 2004-04-06 | Euro-Celtique S.A. | Controlled-release compositions containing opioid agonist and antagonist |
PT1255547E (pt) | 2000-02-08 | 2008-11-24 | Euro Celtique Sa | Composições de libertação controlada contendo agonistas e antagonistas opióides |
EP1935421A1 (en) | 2000-02-08 | 2008-06-25 | Euro-Celtique S.A. | Controlled-release compositions containing opioid agonist and antagonist |
US20050002986A1 (en) * | 2000-05-12 | 2005-01-06 | Robert Falotico | Drug/drug delivery systems for the prevention and treatment of vascular disease |
US8236048B2 (en) | 2000-05-12 | 2012-08-07 | Cordis Corporation | Drug/drug delivery systems for the prevention and treatment of vascular disease |
WO2002009736A1 (en) * | 2000-07-27 | 2002-02-07 | Washington University | Methods and agents for treating persistent pain |
WO2002026139A1 (en) | 2000-09-29 | 2002-04-04 | Cordis Corporation | Coated medical devices |
UA81224C2 (uk) | 2001-05-02 | 2007-12-25 | Euro Celtic S A | Дозована форма оксикодону та її застосування |
CN1525851A (zh) | 2001-05-11 | 2004-09-01 | ������ҩ������˾ | 抗滥用阿片样物质控释剂型 |
PT1416842E (pt) * | 2001-07-18 | 2009-03-31 | Euro Celtique Sa | Composições farmacêuticas de oxicodona e naloxona |
PL367427A1 (en) | 2001-08-06 | 2005-02-21 | Euro-Celtique S.A. | Opioid agonist formulations with releasable and sequestered antagonist |
US20030068375A1 (en) | 2001-08-06 | 2003-04-10 | Curtis Wright | Pharmaceutical formulation containing gelling agent |
WO2003013433A2 (en) | 2001-08-06 | 2003-02-20 | Euro-Celtique S.A. | Sequestered antagonist formulations |
US20030044458A1 (en) | 2001-08-06 | 2003-03-06 | Curtis Wright | Oral dosage form comprising a therapeutic agent and an adverse-effect agent |
CA2457011C (en) * | 2001-08-20 | 2012-04-24 | Maiken Nedergaard | Treatment of glial tumors with glutamate antagonists |
EP1298581A1 (fr) * | 2001-09-27 | 2003-04-02 | C.S.E.M. Centre Suisse D'electronique Et De Microtechnique Sa | Procédé et dispositif pour calculer les valeurs des neurones d'un réseau neuronal |
MXPA04009713A (es) | 2002-04-05 | 2005-01-11 | Euro Celtique Sa | Preparacion farmaceutica que contiene oxicodona y naloxona. |
DK1551372T3 (en) | 2002-09-20 | 2018-07-23 | Alpharma Pharmaceuticals Llc | SEQUERATION SUBSTANCES AND RELATED COMPOSITIONS AND PROCEDURES |
US20040082543A1 (en) * | 2002-10-29 | 2004-04-29 | Pharmacia Corporation | Compositions of cyclooxygenase-2 selective inhibitors and NMDA receptor antagonists for the treatment or prevention of neuropathic pain |
US20040152694A1 (en) * | 2003-02-04 | 2004-08-05 | Istvan Kurucz | Methods and compositions for treating inflammatory disorders of the airways |
US20040202717A1 (en) | 2003-04-08 | 2004-10-14 | Mehta Atul M. | Abuse-resistant oral dosage forms and method of use thereof |
MY135852A (en) | 2003-04-21 | 2008-07-31 | Euro Celtique Sa | Pharmaceutical products |
EP1663229B1 (en) | 2003-09-25 | 2010-04-14 | Euro-Celtique S.A. | Pharmaceutical combinations of hydrocodone and naltrexone |
EP1604666A1 (en) * | 2004-06-08 | 2005-12-14 | Euro-Celtique S.A. | Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD) |
SI1765292T1 (en) | 2004-06-12 | 2018-04-30 | Collegium Pharmaceutical, Inc. | Formulations of medicines to discourage abuse |
EP1702558A1 (en) * | 2005-02-28 | 2006-09-20 | Euro-Celtique S.A. | Method and device for the assessment of bowel function |
WO2007149438A2 (en) * | 2006-06-19 | 2007-12-27 | Alpharma, Inc. | Pharmaceutical compositions |
US20100151014A1 (en) * | 2008-12-16 | 2010-06-17 | Alpharma Pharmaceuticals, Llc | Pharmaceutical composition |
US8623418B2 (en) | 2007-12-17 | 2014-01-07 | Alpharma Pharmaceuticals Llc | Pharmaceutical composition |
PE20110422A1 (es) * | 2008-07-07 | 2011-07-01 | Euro Celtique Sa | Composicion farmaceutica que comprende antagonistas opioides |
MY152279A (en) | 2009-03-10 | 2014-09-15 | Euro Celtique Sa | Immediate release pharmaceutical compositions comprising oxycodone and naloxone |
US10668060B2 (en) | 2009-12-10 | 2020-06-02 | Collegium Pharmaceutical, Inc. | Tamper-resistant pharmaceutical compositions of opioids and other drugs |
EP2338492A1 (en) | 2009-12-24 | 2011-06-29 | Universidad del Pais Vasco | Methods and compositions for the treatment of alzheimer |
EA032906B1 (ru) | 2010-12-22 | 2019-08-30 | Пэдью Фарма Л.П. | Твердая лекарственная форма с контролируемым высвобождением и способы ее получения и применения |
KR101458334B1 (ko) | 2010-12-23 | 2014-11-04 | 퍼듀 퍼머 엘피 | 탬퍼 저항성 고체 경구 투여 형태 |
US9737531B2 (en) | 2012-07-12 | 2017-08-22 | Glytech, Llc | Composition and method for treatment of depression and psychosis in humans |
CN102936223A (zh) * | 2012-11-02 | 2013-02-20 | 江苏中丹药物研究有限公司 | 5-碘-2-甲基苯并咪唑的合成方法及纯化方法 |
KR102278760B1 (ko) * | 2012-12-20 | 2021-07-20 | 큉-빈 루 | 방사선과 조합하여 사용하는 할로겐- 및 디아미노-를 포함하는 방사선 증감제 화합물 |
CN105120846B (zh) | 2013-02-05 | 2019-10-18 | 普渡制药公司 | 抗篡改的药物制剂 |
US10751287B2 (en) | 2013-03-15 | 2020-08-25 | Purdue Pharma L.P. | Tamper resistant pharmaceutical formulations |
CN103275021B (zh) * | 2013-05-24 | 2015-05-20 | 东北农业大学 | N-二氯乙酰基-6,7-二氯-1,2,3,4-四氢喹喔啉及其制备方法 |
UA116567C2 (uk) | 2013-07-23 | 2018-04-10 | Євро-Селтік С.А. | Комбінація оксикодону та налоксону для застосування в лікуванні болю у пацієнтів, які страждають від болю та захворювання, що призводить до дисбактеріозу кишечнику та/або підвищує ризик кишкової бактеріальної транслокації |
WO2015059088A1 (de) | 2013-10-23 | 2015-04-30 | Bayer Cropscience Ag | Substituierte chinoxalin-derivate als schädlingsbekämpfungsmittel |
US9737530B1 (en) | 2016-06-23 | 2017-08-22 | Collegium Pharmaceutical, Inc. | Process of making stable abuse-deterrent oral formulations |
JP7305560B2 (ja) | 2017-06-12 | 2023-07-10 | グリテック, エルエルシー | Nmdaアンタゴニスト及びd2/5ht2a又は選択的5ht2aアンタゴニストによるうつ病の治療 |
WO2019018241A1 (en) * | 2017-07-18 | 2019-01-24 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | RECEPTOR MODULATORS AND METHODS OF USE THEREOF |
CN109678727A (zh) * | 2018-12-26 | 2019-04-26 | 深圳市华先医药科技有限公司 | 一种微通道硝化反应合成2-乙基-5-硝基苯胺的方法 |
Family Cites Families (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3962440A (en) * | 1973-12-26 | 1976-06-08 | Eli Lilly And Company | Quinoxaline compounds as hypnotic agents |
US3992378A (en) * | 1973-12-26 | 1976-11-16 | Eli Lilly And Company | Fluoralkyl quinoxadinediones |
DE2446543A1 (de) * | 1974-09-28 | 1976-04-15 | Hoechst Ag | Wasserunloesliche monoazomethinfarbstoffe, verfahren zu ihrer herstellung und ihre verwendung |
DE2451049A1 (de) * | 1974-10-26 | 1976-04-29 | Hoechst Ag | Perinon-verbindungen, verfahren zu ihrer herstellung und ihre verwendung als farbmittel |
DE2847285A1 (de) * | 1978-10-31 | 1980-05-14 | Hoechst Ag | Monoazoverbindungen, verfahren zu ihrer herstellung und ihre verwendung |
US4659713A (en) * | 1984-10-01 | 1987-04-21 | International Minerals & Chemical Corp. | Quinoxalinedione compounds useful for controlling coccidiosis |
US4803270A (en) * | 1986-03-10 | 1989-02-07 | Sumitomo Chemical Company, Limited | Process of producing fluoroaniline derivatives |
US4812458A (en) * | 1986-09-16 | 1989-03-14 | A/S Ferrosan | 6,7-disubstituted-2,3-dihydroxyquinoxaline compounds, pharmaceutical compositions thereof, and their use as neuroleptics |
IE66149B1 (en) * | 1986-09-16 | 1995-12-13 | Novo Nordisk As | Quinoxaline compounds and their preparation and use |
DK146787A (da) * | 1987-03-23 | 1988-09-24 | Ferrosan | Heterocykliske forbindelser, deres fremstilling og anvendelse |
NO179551C (no) * | 1987-11-10 | 1996-10-30 | Novo Nordisk As | Analogifremgangsmåte for fremstilling av terapeutisk virksomme kinoxalinforbindelser |
DK160941C (da) * | 1988-06-28 | 1991-10-21 | Novo Nordisk As | Kondenserede 2,3-dihydroxypyraziner, fremgangsmaade til deres fremstilling og farmaceutiske praeparater, hvori forbindelserne indgaar |
DK716188D0 (da) * | 1988-12-22 | 1988-12-22 | Ferrosan As | Quinoxalinforbindelser, deres fremstilling og anvendelse |
DK715888D0 (da) * | 1988-12-22 | 1988-12-22 | Ferrosan As | Quinoxalinforbindelser, deres fremstilling og anvendelse |
US5308845A (en) * | 1988-12-22 | 1994-05-03 | Novo Nordisk A/S | Quinoxaline compounds and their preparation and use |
US5187171A (en) * | 1989-01-09 | 1993-02-16 | G. D. Searle & Co. | Use of a glycine b partial agonist as an antipsychotic |
JP2722250B2 (ja) * | 1989-05-30 | 1998-03-04 | 興和株式会社 | 新規なジアミン化合物及びこれを含有する脳機能障害改善剤 |
US5055465A (en) * | 1989-05-31 | 1991-10-08 | Berlex Laboratories, Inc. | Imidazoquinoxalinones, their aza analogs and process for their preparation |
US4994460A (en) * | 1989-06-01 | 1991-02-19 | Bristol-Myers Squibb Co. | Agents for treatment of brain ischemia |
US5055470A (en) * | 1989-06-01 | 1991-10-08 | Bristol-Myers Squibb Co. | Method of treatment of ischemia in brain |
US4975430A (en) * | 1989-06-16 | 1990-12-04 | The State Of Oregon Acting By And Through The State Board Of Education On Behalf Of The Oregon Health Sciences University | CNQX and its analogs as therapeutics for degenerative neural diseases |
US5198461A (en) * | 1989-12-11 | 1993-03-30 | Neurosearch A/S | Isatine derivatives, their preparation and use |
HU214591B (hu) * | 1989-12-14 | 1998-04-28 | Novartis Ag. | Eljárás egy naftoxazinszármazék malonátsójának és az ilyen hatóanyagot tartalmazó gyógyszerkészítmények előállítására |
DK69790D0 (da) * | 1990-03-16 | 1990-03-16 | Novo Nordisk As | Heterocykliske forbindelser, deres fremstilling af anvendelse |
US5268378A (en) * | 1990-05-31 | 1993-12-07 | Merck Sharp & Dohme, Limited | Dioxo-tetrahydroquinoline derivatives |
GB9022785D0 (en) * | 1990-10-19 | 1990-12-05 | Merck Sharp & Dohme | Therapeutic agents |
DK0556393T3 (da) * | 1990-11-06 | 2000-10-16 | Yamanouchi Pharma Co Ltd | Tilkondenseret pyrazinderivat |
AU9049391A (en) * | 1990-12-20 | 1992-07-22 | Warner-Lambert Company | 2-acylamido derivatives of 3,4-dihydro-3-oxo-quinoxaline having pharmaceutical activity |
PT99864B (pt) * | 1990-12-21 | 1999-06-30 | Schering Ag | Processo para a preparacao de novas composicoes farmaceuticas contendo antagonistas de receptor de quisqualato |
GB9100028D0 (en) * | 1991-01-02 | 1991-02-20 | Ici Plc | Compounds |
US5118675A (en) * | 1991-02-15 | 1992-06-02 | American Home Products Corporation | Quinoxaline phosphono-amino acids |
AU660969B2 (en) * | 1991-02-27 | 1995-07-13 | Merrell Pharmaceuticals Inc. | NMDA antagonists |
DK73091D0 (da) * | 1991-04-22 | 1991-04-22 | Novo Nordisk As | Quinoxalinforbindelser, deres fremstilling og anvendelse |
US5196421A (en) * | 1991-06-05 | 1993-03-23 | Eli Lilly And Company | Excitatory amino acid receptor antagonists in methods for the use thereof |
PT101004B (pt) * | 1991-10-26 | 1999-10-29 | Schering Ag | Derivados da quinoxalina, processo para a sua preparacao e composicoes farmaceuticas que os contem |
DE4217952A1 (de) * | 1992-05-30 | 1993-12-02 | Basf Ag | Chinoxalin-2,3(1H,4H)-dione |
CA2098446A1 (en) * | 1992-09-30 | 1994-03-31 | Eckard Weber | 2,5-dihydro-2,5-dioxo-1h-azepines and 2,5-dihydro-2-oxo-1h-azepines and the use thereof as excitatory amino acid and glycine receptor antagonists |
US5352683A (en) * | 1993-03-05 | 1994-10-04 | Virginia Commonwealth University Medical College Of Virginia | Method for the treatment of chronic pain |
IL109397A0 (en) * | 1993-04-28 | 1994-07-31 | Schering Ag | Quinoxalinedione derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same |
-
1993
- 1993-06-17 EP EP93916620A patent/EP0647137B1/en not_active Expired - Lifetime
- 1993-06-17 DE DE69334237T patent/DE69334237D1/de not_active Expired - Lifetime
- 1993-06-17 WO PCT/US1993/005859 patent/WO1994000124A1/en active Application Filing
- 1993-06-17 JP JP50247594A patent/JP3301024B2/ja not_active Expired - Fee Related
- 1993-06-17 KR KR1019940704688A patent/KR100304017B1/ko not_active IP Right Cessation
- 1993-06-17 AU AU46412/93A patent/AU672617B2/en not_active Ceased
- 1993-06-17 CA CA002138026A patent/CA2138026C/en not_active Expired - Lifetime
- 1993-06-17 DK DK93916620T patent/DK0647137T3/da active
- 1993-06-17 AT AT93916620T patent/ATE404201T1/de active
- 1993-06-17 PT PT93916620T patent/PT647137E/pt unknown
- 1993-06-17 ES ES93916620T patent/ES2313714T3/es not_active Expired - Lifetime
- 1993-06-17 NZ NZ254404A patent/NZ254404A/xx not_active IP Right Cessation
- 1993-11-05 US US08/148,259 patent/US5514680A/en not_active Expired - Lifetime
-
1994
- 1994-12-20 NO NO944942A patent/NO310022B1/no not_active IP Right Cessation
- 1994-12-21 FI FI946005A patent/FI120094B/sv not_active IP Right Cessation
-
1995
- 1995-03-17 US US08/405,713 patent/US5622952A/en not_active Expired - Lifetime
- 1995-03-17 US US08/405,708 patent/US5620979A/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
DE69334237D1 (de) | 2008-09-25 |
NZ254404A (en) | 1997-08-22 |
AU672617B2 (en) | 1996-10-10 |
EP0647137A1 (en) | 1995-04-12 |
FI120094B (sv) | 2009-06-30 |
KR100304017B1 (ko) | 2001-11-22 |
US5620979A (en) | 1997-04-15 |
NO944942D0 (no) | 1994-12-20 |
JP3301024B2 (ja) | 2002-07-15 |
FI946005A (sv) | 1995-02-21 |
EP0647137A4 (en) | 1998-09-16 |
PT647137E (pt) | 2008-11-24 |
CA2138026A1 (en) | 1994-01-06 |
WO1994000124A1 (en) | 1994-01-06 |
EP0647137B1 (en) | 2008-08-13 |
FI946005A0 (sv) | 1994-12-21 |
US5514680A (en) | 1996-05-07 |
ATE404201T1 (de) | 2008-08-15 |
NO310022B1 (no) | 2001-05-07 |
AU4641293A (en) | 1994-01-24 |
US5622952A (en) | 1997-04-22 |
DK0647137T3 (da) | 2008-12-08 |
JPH08501283A (ja) | 1996-02-13 |
ES2313714T3 (es) | 2009-03-01 |
NO944942L (no) | 1995-02-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2138026C (en) | Novel 1,4-dihydroquinoxaline-2,3-diones and uses therefor as glycine receptor antagonists | |
AU699353B2 (en) | Alkyl, azido, alkoxy, and fluoro-substituted and fused quinoxalinediones and the use thereof as glycine receptor antagonists | |
US5597922A (en) | Glycine receptor antagonist pharmacophore | |
WO2022037650A1 (en) | Bridged bicyclic compounds as btk inhibitors | |
JPH05505810A (ja) | キノキサリン化合物並びにその製造及び使用 | |
US5652368A (en) | 1,2,3,4-tetrahydroquinoline 2,3,4-trione-3 or 4-oximes | |
CA1131631A (en) | Quinazoline derivatives and pharmaceutical preparations | |
HUT72064A (en) | Oxopyridinylquinoxaline derivative and pharmaceutical compositions containing them | |
US5622965A (en) | 4-hydroxy-3-nitro-1,2-dihydroquinolin-2-ones and the use thereof as excitatory amino acid and glycine receptor antagonists | |
US6372745B1 (en) | 2,3,4,4A-tetrahydro-1H-pyrazino[1,2-A]quinoxalin-5(6H)one derivatives | |
JPH08508271A (ja) | Eaa拮抗体としてのイミダゾロキノキサリノン誘導体 | |
KR20220054286A (ko) | 눈 장애의 치료를 위한 화합물 | |
WO1994007500A1 (en) | 2,5-dihydro-2,5-dioxo-1h-azepines and 2,5-dihydro-2-oxo-1h-azepines and the use thereof as excitatory amino acid and glycine receptor antagonists | |
PL174418B1 (pl) | Nowe związki, pochodne pirydo [1,2,3-de] chinoksaliny i sposób wytwarzania nowych związków, pochodnych pirydo [1,2,3-de] chinoksaliny |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |
Effective date: 20130618 |
|
MKEC | Expiry (correction) |
Effective date: 20131009 |